MitchellRosner Univeristy of Virginia HealthUnited States

MitchellRosner
Mitchell H. Rosner, MD, FACPrChairman, Department of MedicinerAssociate Professor of MedicinerUniversity of Virginia Health SystemrCharlottesville, VirginiarrMitchell Rosner, MD, FACP is the Henry B. Mulholland Professor of Medicine in the Division of Nephrology and Chairman for the Department of Medicine at the University of Virginia. He received his medical degree from the Medical College of Georgia, and completed his residency and a fellowship at the University of Virginia. He is board certified in internal medicine and nephrology.rrDr. Rosner has a strong interest in education and serves on a number of national committees devoted to educational aspects of medical training. Dr. Rosner is the recipient of numerous honors including the University of Virginia All-University Teaching Award and the University Master Educator Award. rrHis clinical practice focus is the medical care of patients with all forms of kidney disease—from acute kidney failure to end-stage kidney disease. His special interest in patients with polycystic kidney disease led Dr. Rosner to found the first regional clinic to specifically address the clinical management of patients with polycystic kidney disease. Dr. Rosner serves as the medical director for this multidisciplinary, patient-centered clinic that also provides selected patients the opportunity to enroll in clinical trials investigating novel therapies for this disease. rrHis research interests include the pathogenesis and management of disorders of sodium and water balance, the treatment of polycystic kidney disease, and the development of novel therapeutics for acute kidney injury. Most recently, he chaired the international consensus group on exercise-associated hyponatremia.rrDr. Rosner has published over 100 articles in peer-reviewed medical journals, and serves on the editorial boards of numerous journals including the American Journal of Kidney Disease and the Clinical Journal of the American Society of Nephrology
Upload Picture
https://storage.unitedwebnetwork.com/files/1099/b5b078a900c3c9cbe509540c1bc04749.jpeg
First Name
Mitchell
Last Name
Rosner
Institution
Country.
United States

Friday, February 7, 2025

Time Session
9:45 a.m.
11:15 a.m.
GeorgiAbraham Chair abraham_georgi@yahoo.comMGM Healthcare, Chennai, IndiaIndia
KriangTungsanga Chair kriangtungsanga@hotmail.comDepartment of Medicine, Faculty of Medicine, Chulalongkorn UnviersityThailand
  • Renal Complications of Novel Cancer Therapies: Practical Insights
    AnushreeShirali Speaker
  • Immune Checkpoint Inhibitors and AKI
    MitchellRosner Speaker Univeristy of Virginia HealthUnited States
  • Electrolyte Abnormalities in the Cancer Patient
    JolantaMalyszko Speaker Medical University of Warsaw, PolandPoland
  • Opening an Onconephrology Clinic - What Should You Be Aware of?
    KenarJhaveri Speaker United States
  • Q&A
Amaltas A Hall B101A

Thursday, February 6, 2025

Time Session
9 a.m.
11 a.m.
KenarJhaveri Chair United States
ManishaSahay Chair India
MitchellRosner Chair Univeristy of Virginia HealthUnited States
  • New Solutions to Anemia Management in Kidney Failure: The Role of HIF-PH Inhibitors
    JolantaMalyszko Speaker Medical University of Warsaw, PolandPoland
  • New Solutions to Phosphorus Control in Kidney Failure: Achieving Patient Goals
    KrishnaswamySampathkumar Speaker Meenakshi Mission Hospital India
  • Improving Volume and Hypertension Control in Kidney Failure: New Approaches to a Critical Issue?
    Angela Yee-MoonWang Speaker Hong Kong/SingaporeSingapore
  • Q and A
Neelkamal Hall 305
11:30 a.m.
1:30 p.m.
KenarJhaveri Chair United States
ManishaSahay Chair India
MitchellRosner Chair Univeristy of Virginia HealthUnited States
  • Clinical Trials Overview: Focus on GLP1a, MRA, and SGLT2
    MaartenTaal Speaker University of NottinghamUnited Kingdom
  • SGLT2i Versus GLP1a And/or MRA Versus SGLT2i, And/or Starting All Together: What Should the Clinician Do? My Approach
    KatherineTuttle Speaker University of Washington School of Medicine, Division of NephrologyUnited States
  • SGLT2i Versus GLP1a And/or MRA Versus SGLT2i, And/or Starting All Together: What Should the Clinician Do? My Approach
    MadhukarMisra Speaker misram@health.missouri.eduUnited State
  • Q and A
Neelkamal Hall 305
2:15 p.m.
4:15 p.m.
KenarJhaveri Chair United States
ManishaSahay Chair India
MitchellRosner Chair Univeristy of Virginia HealthUnited States
  • Approaches to the Patient with Severe Hyponatremia and Acute Kidney Injury
    MitchellRosner Speaker Univeristy of Virginia HealthUnited States
  • Approaches to Severe Hypercalcemia
    KenarJhaveri Speaker United States
  • Approaches to Severe Hyperkalemia
    KSNayak Speaker Virinchi HospitalsIndia
  • Q and A
Neelkamal Hall 305